Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform™ Features in Latest Expansion of Immuno-Oncology Biomarker Discovery Applications

On August 1, 2019 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT, incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can impact cancer patients’ ability to respond to immunotherapies and combination therapies Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, reported the latest expansion of its universal cancer immunogenomics platform, ImmunoID NeXT, incorporating several additional features that are pivotal to the understanding of tumor and immune cell interactions and how the nature of these interactions can impact cancer patients’ ability to respond to immunotherapies and combination therapies. These features include the analysis of human leukocyte antigen (HLA) loss of heterozygosity (LOH), the presence (or absence) of seven of the most common oncogenic viruses, as well as the composition of the T-cell receptor (TCR) alpha repertoire, which is complementary to the previously-released TCR beta analysis.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Through the deep interrogation and analysis of approximately 20,000 genes in both DNA and RNA, ImmunoID NeXT consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor- and immune-related components of the tumor microenvironment from a single sample. The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, and in addition to these new features, it simultaneously enables the analysis of:

Tumor escape and primary/acquired drug resistance mechanisms
Adaptive immune cell receptor clonotypes and repertoire clonality
Innate immune cells
Predicted tumor-specific neoantigens
HLA typing and somatic mutations
Neoantigen load and tumor mutational burden (TMB)
Microsatellite instability (MSI) status
Somatic single nucleotide variations (SNVs), insertions/deletions (indels), gene fusions, and copy number alterations (CNAs)
Germline variants

Personalis CSO, Richard Chen, MD, said, "With the integration of these additional capabilities, we’re continuing to demonstrate our commitment to maximizing the biological insights that can be derived from single tumor samples, which are often limited in availability. While the roles of the adaptive immune cells and oncoviruses are well documented in many cancer types, HLA LOH has emerged as an important, potential resistance mechanism to immunotherapy. We’re excited to be one of the first commercial providers of this analysis as part of ImmunoID NeXT, the premier tumor immunogenomics platform for comprehensive biomarker evaluation in both solid and hematologic cancer indications.". These features include the analysis of human leukocyte antigen (HLA) loss of heterozygosity (LOH), the presence (or absence) of seven of the most common oncogenic viruses, as well as the composition of the T-cell receptor (TCR) alpha repertoire, which is complementary to the previously-released TCR beta analysis.

Personalis, Inc. Announces Integration of New ImmunoID NeXT Platform Features in Latest Expansion of Immuno-Oncology Biom
Through the deep interrogation and analysis of approximately 20,000 genes in both DNA and RNA, ImmunoID NeXT consolidates multiple biomarker assays into one, providing a multidimensional view of the tumor- and immune-related components of the tumor microenvironment from a single sample. The platform is an end-to-end solution for immuno- and precision oncology biomarker discovery applications, and in addition to these new features, it simultaneously enables the analysis of:

Tumor escape and primary/acquired drug resistance mechanisms
Adaptive immune cell receptor clonotypes and repertoire clonality
Innate immune cells
Predicted tumor-specific neoantigens
HLA typing and somatic mutations
Neoantigen load and tumor mutational burden (TMB)
Microsatellite instability (MSI) status
Somatic single nucleotide variations (SNVs), insertions/deletions (indels), gene fusions, and copy number alterations (CNAs)
Germline variants
Personalis CSO, Richard Chen, MD, said, "With the integration of these additional capabilities, we’re continuing to demonstrate our commitment to maximizing the biological insights that can be derived from single tumor samples, which are often limited in availability. While the roles of the adaptive immune cells and oncoviruses are well documented in many cancer types, HLA LOH has emerged as an important, potential resistance mechanism to immunotherapy. We’re excited to be one of the first commercial providers of this analysis as part of ImmunoID NeXT, the premier tumor immunogenomics platform for comprehensive biomarker evaluation in both solid and hematologic cancer indications."